CDC NEWS


powered by Surfing Waves


Latest News


What Long COVID Looks Like in Children and Young Adults


22 May 2023

At least 15 million kids have been infected with SARS-CoV-2, the virus that causes COVID-19, but it is unclear how many of them have had or are living with long COVID. The ailment includes symptoms that linger after COVID-19 or symptoms that come back after an absence of weeks or months. A person might feel short of breath, lose their sense of smell, be unable to think clearly, be tired all the time, or have other maladies that can be traced back to COVID-19.


Rapid Progression of Dementia Following COVID-19


03 May 2023

What you need to know COVID-19 can cause long-term problems with thinking, concentrating, and remembering. This condition is commonly known as “brain fog.” Brain fog after COVID-19 has been studied mostly by observing previously healthy people. In a small study supported by the National Institute of Neurological Disorders and Stroke (NINDS), researchers examined the cognitive impact of COVID-19 on people with dementia. The researchers found that having COVID-19 rapidly accelerated the structural and functional brain deterioration of patients with dementia, regardless of the type of dementia being experienced.


Symptoms of Long COVID Differ for People of Different Racial and Ethnic Groups


06 Apr 2023

What you need to know As the COVID-19 pandemic continues, a growing number of people are experiencing long-term symptoms and health problems following SARS-CoV-2 infection, a condition known as Long COVID. However, the likelihood of being diagnosed with Long COVID seems to vary. A study supported by the Researching COVID to Enhance Recovery (RECOVER) Initiative found that the majority of patients from a sample of more than 30,000 patients with a Long COVID diagnosis were White, non-Hispanic, female, and likely to live in more affluent areas with greater access to health care. Because the COVID-19 pandemic has disproportionately affected people from racial and ethnic minorities, this finding may mean that people from those groups are living with Long COVID without a formal diagnosis.


Antiviral Treatment Reduces Likelihood of Severe Illness From Omicron


09 Feb 2023

hat you need to know Antiviral drugs can lower the risk of severe illness and death from viral infections. In 2021, a clinical trial showed that Paxlovid — an antiviral treatment known generically as nirmatrelvir and ritonavir — reduces the risk of severe COVID-19. Since then, the antiviral treatment has been administered more than 7.6 million times and is available by prescription at more than 40,000 locations in the United States. The study that showed the effectiveness of Paxlovid occurred when the Delta variant was the dominant strain of SARS-CoV-2, the virus that causes COVID-19. In a new study supported by the National Institute of Allergy and Infectious Diseases and the National Cancer Institute, researchers have found that the drug still reduces risk of hospitalization and death from the Omicron variant of SARS-CoV-2.


Bivalent boosters provide better protection against severe COVID-19


08 Feb 2023

To date, more than 80% of people in the U.S. have received at least one dose of a vaccine against SARS-CoV-2, the virus that causes COVID-19. The original mRNA vaccines, developed by Moderna and Pfizer-BioNTech, targeted the initial strain of the virus. Since then, different variants of the virus have evolved. These included Delta in 2020 and Omicron in late 2021. Subvariants of Omicron continue to emerge. Currently, ones called BQ.1, BQ.1.1, and XBB.1.5 predominate in the U.S.




Articles


SARS-CoV-2 Vaccines


26 Feb 2021

Shortly after SARS-CoV emerged at the turn of the 21st century, the spike (S) protein (particularly in its prefusion [native] conformation) was identified as the immunodominant antigen of the virus. Evaluation of patients with SARS-CoV-2 revealed that binding and neutralizing antibodies primarily target the receptor-binding domain of the S1 subunit.




SARS-CoV-2 Variants of Concern in the United States—Challenges and Opportunities


17 Feb 2021

. SARS-CoV-2, like other RNA viruses, constantly changes through mutation, with new variants occurring over time. Generally, when new variants become more common, they do so because of some selective advantage to the virus.




The US Regulatory System and COVID-19 Vaccines The Importance of a Strong and Capable FDA


15 Feb 2021

For many in public health and medicine, the coronavirus disease 2019 (COVID-19) pandemic in the US has been a frustrating journey from one disappointment to the next: late access to testing, insufficient staff and inadequate funding for contact tracing, jumbled communications, and, at the end of 2020, a chaotic launch of vaccination efforts.




COVID-19 Vaccination in Pregnant and Lactating Women


08 Feb 2021

Pregnant women with severe or critical coronavirus disease 2019 (COVID-19) infection are at increased risk for preterm birth and pregnancy loss.




Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination


04 Feb 2021

We recently reported the results of a phase 1 trial of a messenger RNA vaccine, mRNA-1273, to prevent infection with SARS-CoV-2; those interim results covered a period of 57 days after the first vaccination.




Enroll for Free